BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced an update on its Roctavian business to focus commercial operations on three markets: the U.S., Germany and Italy. These markets are where the medicine is approved and reimbursed as a severe hemophilia A treatment. The company will adjust its Roctavian efforts and reduce additional investments in development and manufacturing. BioMarin anticipates reducing annual direct Roctavian expenses to approximately $60 million beginning in 2025. The company has already begun operationalizing the reduction of Roctavian expenses this year to achieve $60 million in expenses beginning in full-year 2025. See Also: Neuralink Implants Brain Device In Second Human, Elon Musk Plans 8 More Trials This Year As a result, the company expects Roctavian to be profitable by the end of 2025. The company’s gene therapy manufacturing facility has been placed in “an idle state” until additional doses are needed. At this time, ...